parkinson-2017-scientifictracks-abstracts

8 / 16

Page 36
Notes:
conferenceseries.com
September 25-26, 2017 Chicago, USA
3rd International Conference on
Parkinson’s disease and Movement Disorders
Volume 7, Issue 5 (Suppl) J Alzheimers Dis Parkinsonism, an open access journal
ISSN: 2161-0460 Parkinson 2017
September 25-26, 2017
Novel insights and therapeutics for Parkinson’s disease
Harish C Pant
National Institutes of Health, USA
Besides the hallmark pathology of aggregated phosphorylated neuronal intermediate filament proteins it has been now well
documented that cyclin-dependent kinase 5 (Cdk5), a critical neuronal kinase in nervous system development, function
and survival, when deregulated and hyper activated induces AD, PD and ALS like phenotypes in mice. Under physiological
conditions, Cdk5 activity is tightly regulated. The deregulation and hyper activation of Cdk5/p25 induces neuropathology.
Thus, Cdk5/p25 becomes prime therapeutic target for AD and neurodegenerative diseases associated with the hyper activation
of Cdk5. In order to prevent hyper activation of Cdk5/p25, we have designed several small peptides of p25 on the basis of
Cdk5/p25 crystal structure and checked for competition with p25 and thus inhibiting selectively the hyperactivity of Cdk5, we
discovered a small peptide (p5) comprising of 24 amino acids, inhibited Cdk5 hyper activation. The modification of p5 to TFP5
crosses blood brain barrier (BBB), which was tested in a transgenic AD, PD & ALS models. Post TFP5 injections in AD, PD and
ALS model mice displayed significant reduction in Cdk5/p25 hyperactivity, neuroinflammation and hyperphosphorylation of
cytoskeletal proteins, along with various behavioral rescues. TFP5 does not inhibit normal Cdk5/p35 activity, and therefore has
no toxic side effects. In addition, treatedmice rescued synaptic dysfunction and a reduction in phospho-neuronal intermediated
neurofilaments and neuronal cell death. These results indicate that TFP5 and TP5 have a potential to be a therapeutic target for
AD, PD and ALS neurological diseases.
Biography
Harish C Pant received his M.A. and Ph.D. degrees in Physics from Agra University, Agra, India. His postdoctoral studies were conducted on the mechanisms of
electron and ion transport in model membrane systems at the Department of Biophysics at Michigan State University. He joined the Laboratory of Neurobiology
in the NIMH as a senior staff fellow in 1974 with Dr. Ichiji Tasaki where he studied the function of the axonal cytoskeleton in the squid giant axon. In 1979 he
moved to the NIAAA extending his studies on the neuronal cytoskeleton and the effects of alcohol on its regulation. Dr. Pant moved to the NINDS, Laboratory of
Neurochemistry in 1987 where he is presently chief of the section on Cytoskeleton Regulation.
Harish C Pant, J Alzheimers Dis Parkinsonism 2017, 7:5 (Suppl)
DOI: 10.4172/2161-0460-C1-030